Phase 2 data showed significant improvements in liver fat alongside meaningful weight loss
This effect may be attributed to the appetite-suppressing and weight-reducing effects of GLP-1 RAs, which decrease postprandial lipoprotein secretion and mitigate systemic inflammation
Sources: Wharton S, Lingvay I, Bogdanski P, et al
Gastrointestinal side effects, including nausea, constipation, diarrhea, and vomiting, were the most common complaint in both groups and were generally mild to moderate, occurring mostly during the dose escalation phase.[1] Injection site reactions were more common with tirzepatide (8.6% vs
Compounded semaglutide and tirzepatide are prescribed for documented individual patient need by licensed physicians and prepared by licensed U.S
Its half-life of approximately 5 days enables weekly research dosing